Build your practice and protect the planet

A new FAERS database analysis identified 13 FDA-approved systemic medications with disproportionately high uveitis reporting signals among 7,301 adverse events logged from 2003 to 2024. The strongest associations were seen with cidofovir and rifabutin, alongside notable signals for biologics, MEK inhibitors, BRAF inhibitors and moxifloxacin. While the findings are hypothesis-generating and cannot